---
title: "What's Going On With Eli Lilly Stock On Tuesday?"
description: "Eli Lilly and Co. (LLY) stock fell 4.93% to $768.27 on Tuesday, influenced by Novo Nordisk's reduced 2025 financial outlook for its weight loss drugs. Novo Nordisk lowered its sales growth forecast to"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250642202.md"
published_at: "2025-07-29T17:03:52.000Z"
---

# What's Going On With Eli Lilly Stock On Tuesday?

> Eli Lilly and Co. (LLY) stock fell 4.93% to $768.27 on Tuesday, influenced by Novo Nordisk's reduced 2025 financial outlook for its weight loss drugs. Novo Nordisk lowered its sales growth forecast to 8-14% from 13-21%, citing slower market penetration. Additionally, over 80 bipartisan members urged the FDA to combat counterfeit GLP-1 drugs. Eli Lilly also announced positive topline results from its Phase 3 BRUIN CLL-314 trial for Jaypirca (pirtobrutinib) against Imbruvica (ibrutinib) in chronic lymphocytic leukemia, meeting its primary endpoint.

**Eli Lilly and Co.** LLY stock is trading lower on Tuesday after its weight loss drug rival, **Novo Nordisk A/S** NVO, trimmed its 2025 financial outlook.

The cut marks the second time this year Novo Nordisk has lowered its guidance.

Novo Nordisk now projects 2025 sales growth to be 8-14% at constant exchange rates, a notable reduction from its earlier forecast of 13-21%.

Similarly, the outlook for operating profit growth has been lowered to 10-16% from the previously anticipated 16-24%.

This revised guidance largely stems from a slower-than-expected penetration of its branded GLP-1 treatments, particularly in the United States, a market increasingly impacted by the persistent use of compounded GLP-1 alternatives.

Trending Investment Opportunities

## GLP-1 Drugs

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner **Marty Makary** on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound from flooding the market.

The group wrote the letter urging immediate action against the rising threat of illegal, counterfeit anti-obesity medications entering the U.S.

The group urged the FDA to issue warning letters, pursue civil enforcement, and monitor non-compliant online retailers and compounding pharmacies selling unapproved weight-loss drugs.

In April, after media reports on **Hims & Hers Inc.** HIMS partnering with the company, Eli Lilly said in a statement that it has no affiliation with Hims & Hers.

Zepbound (tirzepatide) can be prescribed by any licensed healthcare professional. People who are commercially insured with coverage for Zepbound may be eligible to pay as little as $25.

## Trial Data

On Tuesday, Eli Lilly also released topline results from the Phase 3 BRUIN CLL-314 trial of Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

**Johnson & Johnson’s** JNJ Imbruvica is a covalent BTK inhibitor.

The study enrolled patients with treatment-naïve CLL/SLL and those previously treated but were BTK inhibitor-naïve.

The study met its primary endpoint of non-inferiority on overall response rate (ORR) as assessed by an independent review committee (IRC) in both the pre-treated and intent-to-treat populations.

ORR favored pirtobrutinib with a nominal P-value for superiority (p <0.05). Progression-free survival (PFS), a key secondary endpoint, was not yet mature at this analysis, but was trending toward pirtobrutinib.

BRUIN CLL-314 is the first ever head-to-head trial versus ibrutinib in CLL to include treatment-naïve patients.

The overall safety profile of pirtobrutinib in BRUIN CLL-314 was similar to previously reported trials. Detailed results will be presented at a medical congress later in 2025.

These data build on the previously reported positive results from the BRUIN Phase 1/2 trial and the Phase 3 BRUIN CLL-321 trial, the first randomized, controlled study ever conducted in an exclusively post-covalent BTK inhibitor population.

The BRUIN CLL-313 Phase 3 study of pirtobrutinib versus chemoimmunotherapy in treatment naïve CLL/SLL is expected to read out later in 2025 and combined with the results of BRUIN CLL-314, will form the basis of regulatory submissions globally.

**Price Action:** LLY stock is down 4.93% at $768.27 at the last check on Tuesday.

-   ***SoFi Technologies Stock Surges On ‘Exceptional’ Q2 Earnings, Raised Guidance***

*Image Via Shutterstock*

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Puzo Michael J 在诺和诺德公司 $NVO 拥有价值 32 万美元的股票持仓 | Puzo Michael J 在第三季度大幅减持了 Novo Nordisk A/S (NYSE:NVO) 的股份，减少幅度达到 86.9%，目前持有 5,775 股，价值 320,000 美元。其他机构投资者也调整了他们的持仓，True  | [Link](https://longbridge.com/en/news/276447697.md) |
| 诺和诺德公司董事会提议再次选举 Lars Rebien Sorensen 担任主席 | 诺和诺德公司董事会提议重新选举拉斯·瑞比恩·索伦森为董事长 | [Link](https://longbridge.com/en/news/276440991.md) |
| 诺和诺德公司提议任命两名新的董事会成员 | 丹麦制药公司诺和诺德公司提议在 3 月 26 日于哥本哈根举行的年度股东大会上新增三名董事会成员。提议的成员包括海伦娜·萨克森、扬·范·德·温克尔和拉莫娜·塞奎拉。萨克森此前已宣布辞去 Sobi 的职务以加入诺和诺德。还提议重新选举董事长拉 | [Link](https://longbridge.com/en/news/276442777.md) |
| 诺和诺德公司：将在 Ozempic 和 Wegovy 专利到期时准备好替代产品 - Berlingske | 丹麦制药公司诺和诺德计划在其药物 Ozempic 和 Wegovy 的专利于 2031 年在欧洲和 2032 年在美国到期时，准备好替代药物。研究负责人马丁·霍尔斯特·朗格表示，某些临床试验中的候选药物可能会在 2030 年前提交审批。有关 | [Link](https://longbridge.com/en/news/276314777.md) |
| 诺和诺德公司获得欧洲委员会批准使用更高剂量的 Wegovy 注射剂 | 2026 年 2 月 17 日东部时间上午 9:25（MT Newswires）-- 诺和诺德公司（NVO）周二表示，欧洲委员会已批准 Wegovy 的 7.2 毫克每周一次的维持剂量，适用于肥胖成年人。诺和诺德公司表示，此次批准是基于欧洲 | [Link](https://longbridge.com/en/news/276138110.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
